romosozumab HCP administration with PFS — Competitive Intelligence Brief

romosozumab HCP administration with PFS (romosozumab HCP administration with PFS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sclerostin inhibitor. Area: Osteoporosis.

phase 3 Sclerostin inhibitor Sclerostin Osteoporosis Small molecule

Target snapshot

romosozumab HCP administration with PFS (romosozumab HCP administration with PFS) — Amgen. Romosozumab is a monoclonal antibody that targets sclerostin, a protein that inhibits bone formation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
romosozumab HCP administration with PFS TARGET	romosozumab HCP administration with PFS	Amgen	phase 3	Sclerostin inhibitor	Sclerostin
Romosozumab followed by Denosumab	Romosozumab followed by Denosumab	National Taiwan University Hospital	marketed	Sclerostin inhibitor followed by RANKL inhibitor	Sclerostin (romosozumab); RANKL (Denosumab)
Romosozumab and Denosumab Cycle Therapy	Romosozumab and Denosumab Cycle Therapy	National Taiwan University Hospital	marketed	Bone-forming agent and antiresorptive agent combination therapy	Sclerostin (romosozumab); RANKL (denosumab)
EVENITY	ROMOSOZUMAB-AQQG	AMGEN INC	marketed		Sclerostin
Evenity	romosozumab	Amgen	marketed		Sclerostin
Romosozumab Prefilled Syringe	Romosozumab Prefilled Syringe	Karen Klahr Miller, MD	phase 3	Monoclonal antibody	Sclerostin
Placebo to Romosozumab	Placebo to Romosozumab	Amgen	phase 3	Sclerostin inhibitor monoclonal antibody	Sclerostin (SOST protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sclerostin inhibitor class)

1. Amgen · 1 drug in this class